Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 receptor agonists include the diabetes drug Ozempic, also known as Wegovy when it’s used for weight loss. The drugs “bring people to their factory settings” by mimicking the GLP-1 hormone, which ...

Given the various co-morbidities associated with obesity, including diabetes and cardiovascular disease, intuitively, it would seem that GLP-1 use for weight loss would reduce overall medical ...